АНТИТЕЛО, СЕЛЕКТИВНОЕ В ОТНОШЕНИИ РЕЦЕПТОРА ЛИГАНДА, ИНДУЦИРУЮЩЕГО АПОПТОЗ И СВЯЗАННОГО С ФАКТОРОМ НЕКРОЗА ОПУХОЛИ, И ЕГО ПРИМЕНЕНИЕ

摘要

The present invention relates to a purified antibody which selectively binds a TRAIL receptor DR4 and shows no binding above 1.5 times background for DR5, DcR1 or DcR2, wherein said antibody, in its soluble form, has in vivo and in vitro apoptosis-inducing activity in target cells expressing DR4, wherein the apoptosis-inducing activity in vitro is characterized by less than 50% target cell viability at antibody concentrations of less than 0.1 µg/ml for use in the treatment of a disease.